Authors: BENNETT CL GOLUB RM CALHOUN EA WEINSTEIN J FISHMAN D LURAIN J ROLAND P MEDIO F BUKOWSKI RM

Citation: Cl. Bennett et al., COST-UTILITY ASSESSMENT OF AMIFOSTINE AS FIRST-LINE THERAPY FOR OVARIAN-CANCER, International journal of gynecological cancer, 8(1), 1998, pp. 64-72

Authors: ROBERTS JA KUDELKA AP SPRIGGS DR MUGGIA F LURAIN J GROVE W KOWAL C

Citation: Ja. Roberts et al., A PHASE-2 STUDY OF CISPLATIN ANALOG CI-973 IN THE TREATMENT OF PATIENTS WITH REFRACTORY, ADVANCED OVARIAN-CANCER, International journal of gynecological cancer, 6(4), 1996, pp. 257-260

Authors: KEMP G ROSE P LURAIN J BERMAN M MANETTA A ROULLET B HOMESLEY H BELPOMME D GLICK J

Citation: G. Kemp et al., AMIFOSTINE PRETREATMENT FOR PROTECTION AGAINST CYCLOPHOSPHAMIDE-INDUCED AND CISPLATIN-INDUCED TOXICITIES - RESULTS OF A RANDOMIZED CONTROL TRIAL IN PATIENTS WITH ADVANCED OVARIAN-CANCER, Journal of clinical oncology, 14(7), 1996, pp. 2101-2112

Authors: LURAIN J

Citation: J. Lurain, CANCER OF THE OVARY, The New England journal of medicine, 330(14), 1994, pp. 1012-1013